To join the online webinar, go to: www.safetyleaders.org

Online Access Password: Webinar1 (case-sensitive)

Welcome to theNQF Safe Practices for Better Healthcare Webinar:

Updated 2010 CLABSI and SSI Practices: A New Standard of Care(Safe Practices 21-22)

Hosted by NQF and TMIT

2

Charles Denham, MDChairman, TMIT

Co-chairman, NQF Safe Practices Consensus CommitteeChairman, Leapfrog Safe Practices Program

Safe Practices WebinarFebruary 18, 2010

Welcome and Safe PracticeOverview

3

5

Panelists

Charles Denham: Welcome and Safe Practices Overview

Peter Angood: HAI Clinical and Financial Implications and Policy Future

Rabih Darouiche: New Highlights in CLABSI and SSI Prevention

Rabih DarouichePeter AngoodCharles Denham

6

Panelists

David Classen: Future Picture of Prevention of HAIs

Mary Oden Challenges for Infection Preventionists

Jennifer Dingman: The Role of the Patient Advocate

Jennifer DingmanMary OdenDavid Classen

7

The Role of the Patient Advocate

Jennifer Dingman Founder of Persons United Limiting Substandards and

Errors in Healthcare (PULSE), Colorado DivisionCo-founder, PULSE American Division

Safe Practices WebinarFebruary 18, 2010

8

Harmonization – The Quality Choir

2010 NQF Safe Practices for Better Healthcare: A Consensus Report

34 Safe Practices

• Criteria for Inclusion

• Specificity

• Benefit

• Evidence of Effectiveness

• Generalization

• Readiness

9

1010

Information Management and Continuity of Care

Medication Management

Healthcare-Associated Infections

Condition- & Site-Specific Practices

Consent & Disclosure

Culture

Workforce

Consent and Disclosure

CHAPTER 7: Hospital-Associated Infections• Hand Hygiene• Influenza Prevention• Central Venous Catheter-Related Blood Stream

Infection Prevention • Surgical-Site Infection Prevention• Care of the Ventilated Patient and VAP • MDRO Prevention• UTI Prevention

Information Management and Continuity of Care

Medication Management

Healthcare-Associated Infections

Condition-, Site-, and Risk-Specific Practices

Consent & Disclosure

Wrong-siteSx Prevention

Press. Ulcer Prevention

DVT/VTE Prevention

Anticoag. Therapy

VAP Prevention

Central V. Cath.BSI Prevention

Sx-Site Inf.Prevention

Contrast Media Use

Hand HygieneInfluenza

Prevention

Pharmacist Systems Leadership:High-Alert, Std. Labeling/Pkg., and Unit-Dose

Med. Recon.

Culture

CPOE

Read-Back & Abbrev.

Discharge System

PatientCare Info.

LabelingStudies

Culture Meas.,FB., and Interv.

Structuresand Systems

ID and Mitigation Risk and Hazards

Team Trainingand Team Interv.

Nursing Workforce

ICU CareDirect

Caregivers

Workforce CHAPTER 4: Workforce• Nursing Workforce• Direct Caregivers• ICU Care

CHAPTER 2: Creating and Sustaining a Culture of Patient Safety (Separated into Practices]

Leadership Structures and Systems Culture Measurement, Feedback, and Interventions Teamwork Training and Team Interventions Identification and Mitigation of Risks and Hazards

CHAPTER 5: Information Management and Continuity of Care

Patient Care Information Order Read-Back and Abbreviations Labeling Studies Discharge Systems Safe Adoption of Integrated Clinical Systems including

CPOE

CHAPTER 6: Medication Management Medication Reconciliation Pharmacist Leadership Role Including: High-Alert

Med. and Unit-Dose Standardized Medication Labeling and Packaging

CHAPTER 8:• Wrong-Site, Wrong-Procedure, Wrong-Person

Surgery Prevention • Pressure Ulcer Prevention• DVT/VTE Prevention• Anticoagulation Therapy• Contrast Media-Induced Renal Failure Prevention• Organ Donation• Glycemic Control• Falls Prevention• Pediatric Imaging

Informed Consent

Life-Sustaining Treatment

Disclosure

CHAPTER 3: Informed Consent and Disclosure• Informed Consent• Life-Sustaining Treatment• Disclosure• Care of the Caregiver

Consent and Disclosure

Care of Caregiver

MDROPrevention

UTIPrevention

FallsPrevention

OrganDonation

GlycemicControl

PediatricImaging

12

HAI GuidelinesHAI Guidelines

Before insertion:• Educate healthcare personnel involved in the insertion, care, and

maintenance of central venous catheters (CVCs).At insertion:• Use a catheter checklist at the time of CVC insertion.• Perform hand hygiene prior to catheter insertion or manipulation.• Avoid using the femoral vein for central venous access in adult

patients.• Use a catheter cart or kit with components for aseptic catheter

insertion. • Use maximal sterile barrier precautions.• Use chlorhexidine gluconate 2% and isopropyl alcohol solution as

skin antiseptic preparation in patients over two months of age and allow appropriate drying time per product guidelines.

After insertion:• Use a standardized protocol to disinfect catheter hubs, needleless

connectors, and injection ports before accessing the ports.• Remove nonessential catheters. • Use a standardized protocol for non-tunneled CVCs in adults and

adolescents for dressing care.• Perform surveillance for CLABSI and report the data on a regular

basis.

NQF CLABSI Prevention Safe Practice Specifications: 2010

Update

13

• Educate of healthcare professionals involved in surgical procedures.• Educate the patient and his or her family as appropriate about SSI

prevention. • Conduct periodic risk assessments for SSI.• Ensure that measurement strategies follow evidence-based guidelines.• Provide SSI rate data and prevention outcome measures to key

stakeholders.• Administer antimicrobial agents for prophylaxis.• When hair removal is necessary, use clippers or depilatories. • Maintain normothermia immediately following colorectal surgery. • Control blood glucose during the immediate postoperative period for

cardiac surgery patients. • Preoperatively, use chlorhexidine gluconate 2% and isopropyl alcohol

solution as skin antiseptic preparation, and allow appropriate drying time per product guidelines.

NQF SSI Prevention Safe Practice Specifications: 2010

Update

14

The Association for Professionals in The Association for Professionals in Infection Control & EpidemiologyInfection Control & Epidemiology

• Mission To improve health and patient safety by reducing the risks of

infection and related adverse outcomes.

• The preeminent voice in infection prevention Over 13,000 members worldwide with responsibility for infection prevention, control and hospital epidemiology in a variety of healthcare settings.

APIC Targeting Zero InitiativeAPIC Targeting Zero Initiative• Elimination Guides

Evidence-based strategies to implement CDC guidelines, NQF Safe Practices and recommendations from the SHEA-APIC-IDSA Compendium – Guides to the elimination of SSIs, CR-BSIs, Mediastinitis, C. difficile, VAP and MRSA

(hospital and long term care versions) help you bring science to the bedside– New guides in 2010 on A. baumannii, Hemodialysis and SSIs in orthopedics and oncology

• Research

2006 MRSA & 2007 C. difficile Prevalence Studies, 2010 MRSA II Study

• Education

The most comprehensive program of live and online education to reduce infection, meet new and emerging regulatory requirements and understand the changing legal standard in acute, ambulatory and long term care settings

Visit www.apic.org to learn more.

Visit www.apic.org/targetingzero to learn more about the initiative and to access resources and practical tools

17

HAI Clinical and Financial Implications and Policy

FuturePeter B. Angood, MD, FRCS(C), FACS, FCCMSenior Advisor, Patient Safety, National Quality Forum

Member of Safe Practices Steering CommitteeFormer Chief Patient Safety Officer and Vice President

for The Joint Commission

Safe Practices WebinarFebruary 18, 2010

18

1Stone PW, et al. AJIC 2005; 33:501-5

Background: Impact of HAIs• 5%-10% of hospitalized patients develop an

HAI99,000 deaths per year$20 billion per year1

• Risk of serious HAI complications is highest for patients requiring intensive care

• Increasing number of HAIsSicker patient populationMore complex procedures and equipmentIncreasing antimicrobial resistance

19

Klevens, Edwards, Richards, et al. Pub Health Rep 2007;122:160-6

Estimated Number of Healthcare-Associated Infectionsin U.S. Hospitals by Subpopulation and Major Site

of Infection, United States, 2002

20

HRN = high-risk newborns; WBN = well-baby nurseries; ICU = intensive care unit; SSI = surgical-site infections; BSI = bloodstream infections; UTI = urinary infections; PNEU = pneumonia

SSI20%

BSI11%

UTI36%

PNEU11%

Other22%

133,368

424,060

263,810

129,519

274,098

-967

-21

-28,725

244,385

TOTAL

HRN

WBN

Non-newborn ICU

= SSI

Klevens, Edwards, Richards, et al. Pub Health Rep 2007;122:160-6

Calculation of Estimates of Healthcare-Associated Infectionsin U.S. Hospitals Among Adults and Children Outside

of Intensive Care Units, 2002

21

What Are the Costs of Healthcare-Associated Infections?

• U.S.Total excess costs $32 million to $825

million annuallyMost costs not reimbursed when DRGs are

used or if costs are capitated

Preventing 6% of nosocomial infections offsets cost of $60,000 I.C. program

• UK = cost £111 million/year and 950,000 lost bed days (1987)

• Decrease NI rate by 20%, saves $15 million - $16 million

NQF Safe Practices – 2010:Healthcare-Associated Infections

19. Hand Hygiene20. Influenza Prevention21. CLABSI Prevention22. Surgical-Site Infection Prevention23. Care of the Ventilated Patient24. MDRO Prevention25. Catheter-Associated UTI Prevention

22

23

New Highlights in Central Line-

Associated Bloodstream Infection

and Surgical-Site Infection Prevention

Rabih O. Darouiche, MDVA Distinguished Service Professor

Director, Center of Prostheses Infectionat Baylor College of Medicine

Safe Practices WebinarFebruary 18, 2010

• Co-invented antimicrobial-coated catheters that are licensed by Baylor College of Medicine to Cook Inc

• Received educational and research grants from CareFusion

• Do not plan to discuss off-label and investigational use of devices or drugs

Disclosure Statement

24

• Address similarities and differences between CLABSI and SSI

• Assess the impact of these two infections

• Analyze potentially protective approaches

Overview of Presentation

25

Similarities Between CLABSI and SSI

• Both infections result primarily from breaking skin integrity

• Both infections are caused mostly by skin organisms

• Both infections occur at unacceptably high rates, can be difficult to manage, may require future intervention(s), and are expensive to treat

26

Differences Between CLABSI and SSI

• CLABSI manifests while the catheter is still in place, whereas SSI can manifest at any time after surgery, usually by 30 days post-op

• Microbiologic cause of CLABSI is almost always identified, whereas the microbiologic cause of SSI is unknown in many patients

• Occurrence of CLABSI can be attributed to various healthcare providers, whereas SSI is typically linked to the surgeon

27

Clinical Manifestations of infected CVC

• Exit site infection

• Tunnel infection• Thrombophlebiti

s• BSI

Impact of CLABSI

• Incidence: of the 6 million CVC inserted annually in the U.S., 250,000 result in BSI

• Management: cure often requires removal of the infected catheter and long antibiotic therapy

• Medical sequelae: attributable mortality 5%-25%

• Economic burden: cost of treatment is $10K-$56K; annual cost in U.S., $3 billion–$16.8 billion

29

Annual Death Rates in the U.S. for Selected Infectious Diseases

Nosocomial Infections in the ICU

PNEU27%

OTHER6%LRI

4%EENT

4%CVS4%

GI5%

BSI19%

UTI31%

National Nosocomial Infections Surveillance (NNIS) (97 hospitals)

87% central lines

86% Mechanical Ventilation95% Urinary Catheters

N= 14,177

< 55 = 33%55 – 70 = 32%>70 = 35%

31

30%

70%

44%

56%

0%

10%

20%

30%

40%

50%

60%

70%

80%

Non-CRBSI CRBSI Non-CRBSI CRBSI

Solid Tumor Malignancy Hematologic Malignancy

% o

f B

acte

rem

ia w

ith

C

VC

as

the

sou

rce

Gram-Positive Bacteremia in Cancer Patients: Role of the CVC

32

Difference between Surveillance Definition

(by National Healthcare Safety Network: NHSN)

and Clinical/Microbiologic Definition of CLABSI

• Surveillance definition: includes all cases of BSI in patients with CVC in whom other sites of infection are excluded (catheter-associated BSI varies from from 1.3/1000 cath-days in medical surgical wards to 5.6/1000 cath-days in burn ICU)

• Clinical/microbiologic definition: includes only cases of BSI in patients with CVC in whom other sites of infection are excluded and microbiologic relationship of catheter to BSI exists (catheter-related BSI)

33

Relationship between Catheter Colonization and Bloodstream

Infection

• Principle: catheter colonization is a prelude to catheter-related bloodstream infection

• Objective: to prevent infection by inhibiting catheter colonization

34

IA Recommendations in Upcoming CDC Guidelines for Prevention of

CLABSI

• Staff education and training• Insert CVC in subclavian catheters• Place hemodialysis catheters in jugular or femoral veins• Promptly remove CVC when no longer essential• Hand wash with soap/water or alcohol-based hand rubs• Utilize 2% chlorhexidine-based preparation for skin

cleansing before inserting CVC, during dressing changes, and wiping access ports of needleless catheter systems

• Use sterile gauze or transparent semi-permeable dressings

• Use antimicrobial-impregnated CVC if expected duration of placement >5 days and CLABSI remains higher than goal set by institutions despite comprehensive strategyGuidelines for the Prevention of Intravascular Catheter-related Infections. Atlanta (GA): Centers for Disease Control and Prevention; 2010. [draft]

35

Before insertion:• Educate healthcare personnel involved in the insertion, care, and

maintenance of central venous catheters (CVCs).At insertion:• Use a catheter checklist at the time of CVC insertion.• Perform hand hygiene prior to catheter insertion or manipulation.• Avoid using the femoral vein for central venous access in adult

patients.• Use a catheter cart or kit with components for aseptic catheter

insertion. • Use maximal sterile barrier precautions.• Use chlorhexidine gluconate 2% and isopropyl alcohol solution as

skin antiseptic preparation in patients over two months of age and allow appropriate drying time per product guidelines.

After insertion:• Use a standardized protocol to disinfect catheter hubs, needleless

connectors, and injection ports before accessing the ports.• Remove nonessential catheters. • Use a standardized protocol for non-tunneled CVCs in adults and

adolescents for dressing care.• Perform surveillance for CLABSI and report the data on a regular

basis.

NQF CLABSI Prevention Safe Practice Specifications: 2010

Update

36

Comprehensive Protective Strategy

Infection Control Bundle

• Hand washing• Maximal barrier precautions• 2% chlorhexidine-based skin antisepsis• Avoiding femoral site if possible• Removing unnecessary catheters

37

Although very essential, they: • Are not easily enforceable• Are not very durable• Do not completely prevent

infection• Save some, but not

enough, lives

Potential Limitations of Traditional Infection Control

Measures

Reasons to Optimize Prevention of SSI

• Unacceptably high incidence: the 30 million annual surgical procedures in the U.S. result in 300,000-500,000 cases of SSI

• Difficult management: may require repeated surgical interventions

• Serious medical consequences: tremendous morbidity and occasional mortality

• Soaring economic burden: annual cost of treatment in the U.S. is >$7 billion

39

Perioperative Approaches for Preventing SSI

• Non-antimicrobial approaches

•Normothermia

•Adequate oxygenation

•Tight glucose control

• Antimicrobial approaches

•Systemic antibiotic prophylaxis

•Nasal application of mupirocin

•Skin antisepsis40

Impact of Timing of Systemic Antibiotic Prophylaxis on SSI

41

A Prospective Randomized Trial of Nasal Mupirocin Plus Chlorhexidine

Wash

Rapid identification of nasal carriage by S. aureus followed by a 5-day course of nasal mupirocin plus chlorhexidine wash:• Reduces S. aureus infection (3.4% vs. 7.7%)• Decreases S. aureus SSI by almost 60%

Bode, et al. N Engl J Med 2010;362:9-17

42

Importance of the Skin

• Largest bodily organ

• Protective barrier

• Skin flora most common cause of SSI (and CLABSI)

• 80% of bacteria reside in epidermis

Factors that Support the Need for Optimal Skin

Antisepsis

• Most pathogens that cause SSI are skin flora

• At least 2/3 of cases of SSI are incisional

• Most SSI are considered preventable

• Other preventive measures reduce but do not eliminate SSI

44

Commonly used Preoperative Antiseptics

• Povidone-iodine (Iodophor)• Chlorhexidine gluconate• Alcohol • Combination products: >2 active

agents

45

Comparison of Antimicrobial Activity of Antiseptic

Preparations

Chlorhexidine-based preparations are better than alcohol or iodine-based products in:

• Reducing colonization of vascular catheters

• Preventing contamination of blood cultures

• Decreasing contamination of surgical tissues

46

Pressing Need to Compare Clinical Efficacy of Antiseptic Preparations in

Preventing SSI

• CDC guidelines for prevention of infections related to vascular catheters recommend antiseptic cleansing of the skin with 2% chlorhexidine-containing products

O’Grady, et al. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002;51(RR-10):1-29

• CDC has not previously issued a preference as to type of preoperative skin antiseptics

47

Prospective, Randomized, 6-Center Clinical Trial of 849 Patients

• Population: adult patients scheduled for abdominal or non-abdominal clean-contaminated surgery

• Randomization: hospital-stratified• Intervention: preoperative skin cleansing with:

• ChloraPrep® (2% chlorhexidine gluconate-70% isopropyl alcohol = CA) 26-ml applicators; OR

• 10% povidone-iodine (PI) scrub and paint• Evaluation: SSI was assessed by blinded

evaluators Darouiche, et al. N Engl J Med 2010;362:18-2648

Proportion of Patients with Surgical-Site Infection, According to Type of Infection (Intention-to-Treat Population).

Type of Infection

Chlorhexidine-Alcohol (N=409)no. (%)

Povidone- Iodine

(N=440)no. (%)

Relative Risk(95% CI) P-Value

Any surgical-site infection 39 (9.5) 71 (16.1) 0.59 (0.41-0.85)

0.004

Superficial incisional infection

17 (4.2) 38 (8.6) 0.48 (0.28-0.84)

0.008

Deep incisional infection 4 (1.0) 13 (3.0) 0.33 (0.11-1.01)

0.05

Organ-space infection 18 (4.4) 20 (4.6) 0.97 (0.52-1.80)

>0.99

Sepsis from surgical-site infection

11 (2.7) 19 (4.3) 0.62 (0.30-1.29)

0.26

49

Kaplan-Meier Curves for Freedom from Surgical-Site Infection (Intention-to-Treat Population)

Proportion of Patients with Surgical-Site Infection, According to Type of Surgery (Intention-to-Treat Population).

Chlorhexidine-Alcohol Povidone-Iodine

Type of Surgery Nno.

Infected

(%) Infected N

no. Infected

(%) Infected

Abdominal 297 37 (12.5) 308 63 (20.5)

Colorectal 186 28 (15.1) 191 42 (22.0)

Biliary 44 2 (4.6) 54 5 (9.3)

Small intestinal 41 4 (9.8) 34 10 (29.4)

Gastroesophageal26 3 (11.5) 29 6 (20.7)

Non-abdominal 112 2 (1.8) 132 8 (6.1)

Thoracic 44 2 (4.5) 57 4 (7.0)

Gynecologic 42 0 (0.0) 40 1 (2.5)

Urologic 26 0 (0.0) 35 3 (8.6)51

Chlorhexidine-Alcohol (CA) vs. Povidone-Iodine (PI) for Prevention

of SSI

• CA significantly reduces SSI• Number of patients needed to receive

CA instead of PI to prevent one case of SSI: 17

• Delays onset of SSI • CA and PI have similar rates of

adverse events (including events related to study medication in 0.7% in each group) and serious adverse events

52

New CMS Regulations (effective 10/08) Changes to Inpatient Prospective

Payment System

10 non-reimbursable conditions met these criteria:

• High cost• High volume• Triggers a high-paying MS-DRG• May be considered reasonably preventable

through application of evidence-based guidelines

Federal Register, Volume 73, No. 161; 08/19/08

53

Non-reimbursable Infectious Conditions

• Catheter-associated urinary tract infection

• Vascular catheter-associated infection• Surgical-site infection-mediastinitis

after CABG• Surgery on various joints, including

shoulder, elbow, and spine

54

Perspective

Optimal prevention of CLABSI and SSI can:

• Improve patient care• Incur cost-savings• Enhance infection control measures

55

56

Future Picture of Prevention of Healthcare-

Associated InfectionsDavid Classen, MD, MSChief Medical Officer at CSC

Associate Professor of Medicine at the University of UtahInfectious Diseases Consultant, University of Utah School

of Medicine

Safe Practices WebinarFebruary 18, 2010

57

Challenges for Infection Preventionists

Mary A. Oden, RN, BSN, MHS, CICSenior Director, Cleveland Clinic Health System

Infection Prevention Program

Safe Practices WebinarFebruary 18, 2010

58

The Role of the Patient Advocate

Jennifer Dingman Founder of Persons United Limiting Substandards and

Errors in Healthcare (PULSE), Colorado DivisionCo-founder, PULSE American Division

Safe Practices WebinarFebruary 18, 2010

59

60